Last reviewed · How we verify
Epinephrine (Adrenaline)
Epinephrine (Adrenaline) is a Catecholamine; adrenergic agonist Small molecule drug developed by Aga Khan University. It is currently FDA-approved for Anaphylaxis (acute allergic reaction), Cardiac arrest (cardiopulmonary resuscitation), Severe hypotension/shock.
Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation.
Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation. Used for Anaphylaxis (acute allergic reaction), Cardiac arrest (cardiopulmonary resuscitation), Severe hypotension/shock.
At a glance
| Generic name | Epinephrine (Adrenaline) |
|---|---|
| Sponsor | Aga Khan University |
| Drug class | Catecholamine; adrenergic agonist |
| Target | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine; Cardiovascular; Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Epinephrine binds to alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors on target tissues. This activation increases cardiac contractility and heart rate (beta-1), causes vasoconstriction (alpha-1), and promotes bronchial smooth muscle relaxation (beta-2), making it effective for acute cardiovascular collapse and severe allergic reactions.
Approved indications
- Anaphylaxis (acute allergic reaction)
- Cardiac arrest (cardiopulmonary resuscitation)
- Severe hypotension/shock
- Acute bronchospasm
Common side effects
- Tachycardia
- Hypertension
- Tremor
- Anxiety
- Headache
- Arrhythmias
- Myocardial ischemia
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (PHASE2)
- Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial (NA)
- Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- Parenting and CAH - 21-hydroxylase Deficiency
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epinephrine (Adrenaline) CI brief — competitive landscape report
- Epinephrine (Adrenaline) updates RSS · CI watch RSS
- Aga Khan University portfolio CI
Frequently asked questions about Epinephrine (Adrenaline)
What is Epinephrine (Adrenaline)?
How does Epinephrine (Adrenaline) work?
What is Epinephrine (Adrenaline) used for?
Who makes Epinephrine (Adrenaline)?
What drug class is Epinephrine (Adrenaline) in?
What development phase is Epinephrine (Adrenaline) in?
What are the side effects of Epinephrine (Adrenaline)?
What does Epinephrine (Adrenaline) target?
Related
- Drug class: All Catecholamine; adrenergic agonist drugs
- Target: All drugs targeting Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
- Manufacturer: Aga Khan University — full pipeline
- Therapeutic area: All drugs in Emergency Medicine; Cardiovascular; Allergy/Immunology
- Indication: Drugs for Anaphylaxis (acute allergic reaction)
- Indication: Drugs for Cardiac arrest (cardiopulmonary resuscitation)
- Indication: Drugs for Severe hypotension/shock
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing